Pertussis vaccination in infancy lowers the incidence of pertussis disease and the rate of hospitalisation after one and two doses: Analyses of 10 years of pertussis surveillance

Vaccine

Volumn 30, Issue 21, 2012, Pages 3239-3247

  Nilsson, Lennart ^a,b   Lepp, Tiia ^a   von Segebaden, Kerstin ^a   Hallander, Hans ^a   Gustafsson, Lennart ^a  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Dose related incidence; Hospitalisation; Infants; Pertussis vaccination; Surveillance; Whooping cough

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

AGE; ARTICLE; CHILD; CHILD HOSPITALIZATION; CLINICAL TRIAL (TOPIC); DISEASE SURVEILLANCE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; THERAPY DELAY; VACCINATION;

CHILD; CHILD, PRESCHOOL; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; PERTUSSIS VACCINE; SWEDEN; VACCINATION; WHOOPING COUGH;

EID: 84859515962     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.089     Document Type: Article

References (22)

1. Carlsson RM, Gustafsson L. Ten year Report. Pertussis surveillance in Sweden. Progress report October 1, 1997 -December 31, 2007 with an executive summary. Smittskyddsinstitutets rapportserie No. 4; 2008 [available at]. http://www.smittskyddsinstitutet.se/.
2. Carlsson RM, Gustafsson L. Ten year Report. Pertussis surveillance in Gothenburg study area, technical report October 1, 1997-December 31, 2008, including enhanced surveillance January 1, 2003 until December 31, 2008, with an executive summary. Smittskyddsinstitutets rapportserie No. 4; 2008 [available at Smittskyddsinstitutet.se].
3. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006, 118:978-984.
4. Olin P., Gustafsson L., Barreto L., Hessel L., Mast T.C., Rie A.V., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21:2015-2021.
5. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine, Ad hoc group for the study of pertussis vaccines. Lancet 1997, 350:1569-1577.
6. Ad hoc group for the Study of Pertussis Vaccines Placebo-controlled trial of two acellular pertussis vaccines in Sweden - protective efficacy and adverse events. Lancet 1988, 1(8592):955-960. [Erratum in: Lancet 1998; 1 (8596) 1238].
7. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storseater J. A controlled trial of two-component, three component, and five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355.
8. Trollfors B., Taranger J., Lagergård T., Lind L., Sundh V., Zackrisson G., et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995, 333:1045-1050.
9. Hallander H.O., Andersson M., Gustafsson L., Ljungman M., Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS 2009, 117:912-922.
10. Wood N., McIntyre P., Marshall H., Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010, 29:209-215.
11. de Greeff S.C., Mooi F.R., Westerhof A., Verbakel J.M., Peeters M.F., Heuvelman C.J., et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010, 50:1339-1345.
12. Juretzko P., von Kries R., Hermann M., Wirsing von König C.H., Weil J., Giani G. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 2002, 35:162-167.
13. Mansour M., Brown R.G., Morris A., Smith B., Halperin S.A. Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model. Clin Vaccine Immunol 2007, 14:1381-1383.
14. Mielcarek N., Debrie A.-S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. Pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65. 10.1371/journa.ppat.0020065.
15. Olin P., Gustafsson L., Rasmussen F., Hallander H., Heijbel H., Gottfarb P. Efficacy trial of acellular pertussis vaccines: technical report Trial II with preplanned analyses of efficacy, immunogenicity and safety 1997, 116. Swedish Institute for Infectious Disease Control (SMI-tryck), Stockholm, p. 1-70.
16. Siegrist C.-A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331-3346.
17. Hull B.P., McIntyre P.B. Timeliness of childhood immunisation in Australia. Vaccine 2006, 24:4403-4408.
18. Bobo J.K., Gale J.L., Thapa P.B., Wassilak S.G. Risk factors for delayed immunization in a random sample of 1163 children from Oregon and Washington. Pediatrics 1993, 91:308-314.
19. Funkhouser A.W., Wassilak S.G., Hinman A.R., Orenstein W.A., Mortimer E.A. Age at pertussis immunization as it relates to current epidemiology and disease control. Tokai J Exp Clin Med 1988, 13(Suppl.):111-115.
20. Dannetun E., Tegnell A., Hermansson G., Giesecke J. Parents' reported reasons for avoiding MMR vaccination. A telephone survey. Scand J Prim Health Care 2005, 23:149-153.
21. Siegrist C.-A. Blame vaccine interference, not neonatal immunization, for suboptimal responses after neonatal diphtheria, tetanus, and acellular pertussis immunization. J Pediatr 2008, 153:305-307.
22. ECDC Guidance. Scientific panel on childhood immunisation schedule: diphteria-tetanus-pertussis, Stockholm, November 2009 http://www.ecdc.europa.eu/en/publications/Publications/Forms/ECDC_DispForm.aspx%3FID=458.